Rheostat is a biotechnology company developing treatments for neurodegenerative disease by modulation of mitophagy and autophagy that is headquartered in Cambridge, Massachusetts and was founded in 2018 by Tim Harris, Wade Harper, Ivan Dikic and Josh Resnick.
Rheostat is focusing on molecular pathways involved in clearance of toxic components such as damaged organelles or aggregated proteins because mutations in these pathways cause many neurodegenerative diseases associated with cognitive impairment. Rheostat aims to use knowledge about these clearance pathways to find and develop small molecules that can restore cellular balance for the treatment of neurodegenerative and rare diseases.
Funding
Series A
On November 26, 2018 Rheostat Therapeutics completed their series A funding round with $23 million in funding from MRL Ventures Fund (lead investor), AbbVie Biotech Ventures, SV Health Investors, Dementia Discovery Fund, Amgen Ventures, Alexandria Venture Investments, and the Dementia Discovery Fund.
Timeline
Funding rounds
People
Cristina Csimma
Executive Chair
Darby R. Schmidt
Senior Director, Head of Chemistry
Donato del Camino
Senior Director
J. Stefan Kaczmarek
Senior Director
Joshua Resnick
Board Chair
Magdalene Moran
President and Chief Scientific Officer
Nathaniel Blair
Associate Director of Biology
Further reading
Auto-extract from URL...
Documentaries, videos and podcasts
Auto-extract from URL...
Companies